Navigation Links
Benefits of Breastfeeding Outweigh Risk of Infant Exposure to Environmental Chemicals in Breastmilk
Date:12/16/2008

as contaminated. The authors, eminent authorities on the subject have put these fears to rest," says Ruth A. Lawrence, MD, Editor-in-Chief of Breastfeeding Medicine, from the Department of Pediatrics, University of Rochester School of Medicine and Dentistry.

Breastfeeding Medicineis an authoritative, peer-reviewed, multidisciplinary journal published quarterly. The Journal publishes original scientific papers, reviews, and case studies on a broad spectrum of topics in lactation medicine. It presents evidence-based research advances and explores the immediate and long-term outcomes of breastfeeding, including the epidemiologic, physiologic, and psychological benefits of breastfeeding.

Mary Ann Liebert, Inc., is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Women's Health, Journal of Gynecologic Surgery, and Pediatric Asthma, Allergy and Immunology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 60 journals, books, and newsmagazines is available at www.liebertpub.com

Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801-5215www.liebertpub.com

Phone: (914) 740-2100(800) M-LIEBERT Fax: (914) 740-2101

Contact: Vicki Cohn, Mary Ann Liebert, Inc., (914) 740-2100, ext. 2156, '/>"/>

SOURCE Mary Ann Liebert, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Benefits of a Lifeclinic LC300 Automated Blood Pressure Monitor Recently Featured on Daytime Medical Talk Show
2. Prescription Drug Benefits for Medicare Patients with Cancer to Cost More in 2009
3. Time is Money When People Wait Too Long to Apply for Social Security Disability Benefits
4. Employer Vantage From HealthLeaders-InterStudy Provides a Snapshot of Both Self- and Fully-Insured Health Benefits to Help Pharmaceutical and Diagnostic Manufacturers Identify Business Opportunities
5. Exjade(R) Benefits Chronically Transfused Patients by Significantly Reducing Toxic Iron That Can Damage Key Organs, According to Landmark Trial
6. Integrated Benefits Institute Helps Employers Make the Business Case for Health and Productivity Improvement
7. Pharmacy Benefits Academy Set for 2009
8. Clock Ticking for Millions of Federal Employees Hoping to Avoid Blue Cross/Blue Shield Benefits Cut
9. Integrated Benefits Institute Announces Availability of 2007 IBI Benchmarking Data for Employers to Evaluate Effectiveness of their Health and Productivity Programs
10. States View Limits on Retiree Health Benefits
11. Blue Cross/Blue Shield Christmas Gift to Federal Employees: Surprise, Were Cutting Your Benefits!; Patients, Doctors and Health Care Providers Outraged
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:VidaySalud.com(TM) Reaches 1,000,000 Page Views In its First Six Months of Operation 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 2Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day 3JAG Media Holdings Inc Amends Articles of Incorporation 58781 1JAG Media Holdings Inc Amends Articles of Incorporation 58781 2Vermillion Announces Return of Eric Fung M D Ph D 14338 1Vermillion Announces Return of Eric Fung M D Ph D 14338 2Vermillion Announces Return of Eric Fung M D Ph D 14338 3Hamon Tower Features Critical Care Advances Potential for Reduced Costs 5195 1Hamon Tower Features Critical Care Advances Potential for Reduced Costs 5195 2